VRNA Form 4: Director's RSUs and Options Cashed at $107/ADS
Rhea-AI Filing Summary
Kenneth Cunningham, a director of Verona Pharma plc (VRNA), reported multiple transactions tied to the company's scheme of arrangement with Merck/Parent on 10/07/2025. At the effective time of the arrangement each American Depositary Share (ADS) was entitled to $107 in cash, reflecting $13.375 per ordinary share times eight ordinary shares per ADS. The Form 4 shows a mix of dispositions and cash-conversion events: 79,776 ordinary shares were disposed, 72,000 ordinary-share-equivalent restricted share units were marked as acquired then immediately converted into cash rights, and multiple share options totaling 600,000 options (200,000 + 96,000 + 240,000 + 64,000) vested and were converted into cash where exercisable amounts were cancelled, leaving 0 beneficially owned ordinary shares following the transactions. The filing was signed by an attorney-in-fact on 10/08/2025.
Positive
- Automatic vesting and cash conversion of RSUs ensured immediate liquidity at $107 per ADS equivalent
- In-the-money options converted to cash, delivering value to the reporting person without exercise cost
Negative
- Reporting person holds 0 ordinary shares following the transactions, eliminating director equity ownership
- Cash proceeds subject to withholding taxes, reducing net payout from the conversion
Insights
Director's holdings were fully cashed out under the Merck scheme, leaving no remaining ordinary shares.
The director reported dispositions and automatic cash conversions triggered by the transaction agreement tied to the scheme of arrangement. Time-based RSUs and in-the-money options were accelerated and converted into cash equal to the ADS consideration less applicable exercise prices, consistent with the disclosed transaction mechanics.
Key dependencies include final cash settlement and withholding taxes; monitor for any post-closing adjustments or tax withholding statements in the issuer's disclosures over the next few weeks.
Equity awards (RSUs and options) were vested and cashed out at the ADS consideration, eliminating equity exposure.
Per the transaction terms, outstanding time-based RSUs became fully vested and converted into cash equal to the ADS consideration ($107 per ADS equivalent). Share options with exercise prices below the ADS consideration were converted into cash equal to the excess of the ADS consideration over the exercise price.
This produces a discrete cash payment per award rather than ongoing equity; review any subsequent payroll or company statements for exact cash amounts received and tax withholdings within the standard post-close settlement window.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Share Unit | 72,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 200,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 96,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 240,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 64,000 | $0.00 | -- |
| Disposition | Ordinary Shares | 79,776 | $0.00 | -- |
| Exercise | Ordinary Shares | 72,000 | $0.00 | -- |
| Disposition | Ordinary Shares | 72,000 | $0.00 | -- |
Footnotes (1)
- Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.
